Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective Studies of the effects of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, have suggested similarities to the symptoms of schizophrenia. Our primary goal was to evaluate the dimensions of the Positive and Negative Syndrome Scale (PANSS) in ketamine users (acute and chronic) compared to schizophrenia patients (early and chronic stages). Method We conducted exploratory factor analysis for the PANSS from four groups: 135 healthy subject administrated ketamine or saline, 187 inpatients of ketamine abuse; 154 inpatients of early course schizophrenia and 522 inpatients of chronic schizophrenia. Principal component factor analyses were conducted to identify the factor structure of the PANSS. Results Factor analysis yielded five factors for each group: positive, negative, cognitive, depressed, excitement or dissociation symptoms. The symptom dimensions in two schizophrenia groups were consistent with the established five-factor model (Wallwork et al., 2012). The factor structures across four groups were similar, with 19 of 30 symptoms loading on the same factor in at least 3 of 4 groups. The factors in the chronic ketamine group were more similar to the factors in the two schizophrenia groups rather than to the factors in the acute ketamine group. Symptom severities were significantly different across the groups (Kruskal–Wallis χ2(4) = 540.6, p < 0.0001). Symptoms in the two ketamine groups were milder than in the two schizophrenia groups (Cohen’s d = 0.7). Conclusion Our results provide the evidence of similarity in symptom dimensions between ketamine psychosis and schizophrenia psychosis. The interpretations should be cautious because of potential confounding factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citationThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 1×
“For these reasons, the effects of NMDA receptor antagonists emerge as one of the central models for schizophrenia drug development (Coyle et al., 2002; Javitt, 2008; Nikiforuk et al., 2013; Vollenweider and Kometer, 2010).”
BackgroundSchobel, S. A., Chaudhury, N. H., Khan, U. A., Paniagua, B., Styner, M. A., Asllani, I., Inbar, B. P., Corcoran, C. M., Lieberman, J. A., Moore, H., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.011 · Cited by 549
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Self-citationMorgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02761.x · Cited by 373
Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322 · cited 2×
“However, a small minority of ketamine or phencyclidine abusers (another NMDA antagonist) develops a persisting psychiatric syndrome that has been suggested to resemble “endogenous” psychotic disorders, such as schizophrenia and bipolar disorder (Fauman and Fauman, 1980; Fine and Finestone, 1973; Javitt et al., 2012).”
BackgroundScheidegger, M., Walter, M., Lehmann, M., Metzger, C., Grimm, S., Boeker, H., Boesiger, P., Henning, A., & Seifritz, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044799 · Cited by 282 · cited 1×
“These findings were consistent with other previous studies with ketamine infusion in healthy subjects and frequent ketamine abusers (Morgan et al., 2010; Scheidegger et al., 2012; Zhang et al., 2014), suggesting acutely ketamine administration in healthy subjects has little effect on depressive symptoms.”
ResultKrystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1982-8 · Cited by 272
Self-citationMoghaddam, B., & Krystal, J. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs075 · Cited by 238 · cited 1×
“In both animals and humans, the effects of chronic ketamine administration also have been used as a model for schizophrenia (Moghaddam and Krystal, 2012; Schobel et al., 2013; Stone et al., 2013).”
BackgroundSelf-citationTarabeux, J., Kebir, O., Gauthier, J., Hamdan, F. F., Xiong, L., Piton, A., Spiegelman, D., Henrion, É., Millet, B., S2D team, et al. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.52 · Cited by 231
Cited by
The profile of cognitive impairments in chronic ketamine users
Ke, X., Ding, Y., Xu, K., He, H., Wang, D., Deng, X., Zhang, X., Zhou, Y., Zhou, C., Liu, Y., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.05.050 · Cited by 67
Self-citationCheng, W.-J., Chen, C.-H., Chen, C.-K., Huang, M.-C., Pietrzak, R. H., Krystal, J. H., & Xu, K. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.049 · Cited by 65
Self-citationAboraya, A., & Nasrallah, H. A. (2016) · Annals of Clinical Psychiatry · doi:10.1177/104012371602800206 · Cited by 46
Metadata
- Authors
- Xu, K., Krystal, J. H., Ning, Y., Chen, D. C., He, H., Wang, D., Ke, X., Zhang, X., Ding, Y., Liu, Y., Gueorguieva, R., Wang, Z., Limoncelli, D., Pietrzak, R. H., Petrakis, I. L., Zhang, X., & Fan, N.
- Venue
- Journal of Psychiatric Research
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 61
- Pages
- 64-72
- ISSN
- 0022-3956 (ISSN-L)
- OpenAlex
- W2033483749
- Cited by
- 66
- References
- 12
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. https://app.cochat.ai/papers/10.1016/j.jpsychires.2014.12.012
- The paper
- Xu, K., Krystal, J. H., Ning, Y., Chen, D. C., He, H., Wang, D., Ke, X., Zhang, X., Ding, Y., Liu, Y., Gueorguieva, R., Wang, Z., Limoncelli, D., Pietrzak, R. H., Petrakis, I. L., Zhang, X., & Fan, N. (2015). Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. Journal of Psychiatric Research. https://doi.org/10.1016/j.jpsychires.2014.12.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.